Home » Stocks » CYTK

Cytokinetics, Inc. (CYTK)

Stock Price: $20.09 USD 0.11 (0.55%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $20.08 -0.01 (-0.05%) Jan 21, 5:54 PM
Market Cap 1.43B
Revenue (ttm) 54.32M
Net Income (ttm) -114.00M
Shares Out 68.28M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $20.09
Previous Close $19.98
Change ($) 0.11
Change (%) 0.55%
Day's Open 20.01
Day's Range 19.20 - 20.27
Day's Volume 627,874
52-Week Range 8.75 - 28.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals

GlobeNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan dru...

GlobeNewsWire - 2 weeks ago

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is schedule...

GlobeNewsWire - 4 weeks ago

Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and Licensing Company is Planning Regul...

GlobeNewsWire - 1 month ago

Additional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS Additional Data from FORTITUDE-ALS Support...

GlobeNewsWire - 1 month ago

Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive Hypertrophic Cardiomyopathy with No Dose Interruptions Due...

GlobeNewsWire - 1 month ago

Supplemental Analyses of Primary Composite Endpoint Further Demonstrate Effect of Omecamtiv Mecarbil In Patie nts with Lower Ejection Fraction

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS/M...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2020 it granted stock options to purchase an aggre...

GlobeNewsWire - 1 month ago

Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting

Insider Monkey - 1 month ago

In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the  Top 5 Healthcare Stocks for the Future .

Other stocks mentioned: INSM, AUPH, NEO, TPTX
GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled...

Zacks Investment Research - 1 month ago

Amgen (AMGN) will terminate the collaboration with Cytokinetics and transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to the latter.

Other stocks mentioned: AMGN
GlobeNewsWire - 1 month ago

Company Committed to Advancing Omecamtiv Mecarbil with Initial Focus on Preparation s for Regulatory Interaction s Following Positive Results of GALACTIC-HF

CNBC - 1 month ago

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Amazon and Yelp.

Other stocks mentioned: AMZN, YELP, PDFS
GlobeNewsWire - 2 months ago

Appointment Strengthens Commercial, Market Access and Specialty Sales Expertise as Company Advances Pipeline Toward Potential Commercialization Appointment Strengthens Commercial, Market Acces...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new findings from analyses of claims data and electronic health re...

GlobeNewsWire - 2 months ago

New Findings from Studies of Cardiac Myosin Inhibitors in Animal Models of Hypertrophic Cardiomyopathy and Heart Failure with Preserved Ejection Fraction New Findings from Studies of Cardiac M...

GlobeNewsWire - 2 months ago

Trial Met Primary Composite Endpoint of Reduction in Heart Failure Events or Cardiovascular Death; Did Not Meet Secondary Endpoints Including Reduction in Cardiovascular Death

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 30, 2020 it granted stock options to purchase an aggreg...

GlobeNewsWire - 2 months ago

Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session

Seeking Alpha - 2 months ago

Cytokinetics, Inc. (CYTK) CEO Robert Blum on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Cytokinetics (CYTK) delivered earnings and revenue surprises of 91.53% and 997.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 2 months ago

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 2 months ago

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 202...

GuruFocus - 3 months ago

Amgen Inc. (NASDAQ:AMGN) and its partner, Cytokinetics Inc. (NASDAQ:CYTK), took a punch to the gut last week when the heart drug they were collaborating on failed to meet expectations. Thousan...

Other stocks mentioned: AMGN
Investors Business Daily - 3 months ago

Amgen and Cytokinetics disappointed with key Phase 3, final-stage trial results for a heart treatment that aims to reduce cardiovascular death; sending CYTK crashing and AMGN down hard. The po...

Other stocks mentioned: AMGN
GlobeNewsWire - 3 months ago

Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events 

Zacks Investment Research - 3 months ago

Cytokinetics (CYTK) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 3 months ago

Real-World Population Representative of P atients Enrolled in GALACTIC-HF  I ndicate a H igh- N eed, H igh- R isk P opulation with Heart Failure

GlobeNewsWire - 3 months ago

Heart Failure Patients in Phase 3 Clinical Trial of Omecamtiv Mecarbil Are at High Risk of Cardiovascular Events and Symptom Burden

Zacks Investment Research - 3 months ago

Investors need to pay close attention to Cytokinetics (CYTK) stock based on the movements in the options market lately.

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data will be presented at the Heart Failure Society of Amer...

GlobeNewsWire - 3 months ago

Grant s Suppor t Community Engagement for Patient Advocacy Organization s Focused on Cardiovascular and Neuromuscular Diseases

GlobeNewsWire - 3 months ago

Company Advances Second Cardiac Myosin Inhibitor Company Advances Second Cardiac Myosin Inhibitor

GlobeNewsWire - 4 months ago

Trial Proceeding Toward Conclusion, Topline Results Expected in Q4 2020 Trial Proceeding Toward Conclusion, Topline Results Expected in Q4 2020

GlobeNewsWire - 4 months ago

ELK GROVE VILLAGE, Ill. and SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cure SMA and Cytokinetics (Nasdaq:CYTK) today announced the renewal of their partnership to increas...

GlobeNewsWire - 5 months ago

Company Makes Long-term Commitment to Outcomes Research in HCM Company Makes Long-term Commitment to Outcomes Research in HCM

Seeking Alpha - 5 months ago

Cytokinetics, Incorporated's (CYTK) CEO Robert Blum on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Top-line Results from GALACTIC-HF Expected in Q4 2020

Zacks Investment Research - 5 months ago

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 20...

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the closing of its previously announced underwritten public offering o...

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the pricing of an underwritten public offering of 7,291,667 shares of ...

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced plans to offer, subject to market and other conditions, $150,000,000 o...

GlobeNewsWire - 6 months ago

Topline Results from GALACTIC-HF,  Phase 3 Clinical Trial of Omecamtiv Mecarbil, Cardiac Myosin Activator, Expected in Q4

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)--Headline of release should read: RTW Investments, LP, Ji Xing Pharmaceuticals and Cytokinetics Enter Into Strategic Financing Collaboration to Support the Developmen...

GlobeNewsWire - 6 months ago

$250 Million in Committed Capital to Cytokinetics; Additional $200 Million in Development and Commercialization Milestone Payments

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is participating in the launch of Kainomyx, Inc., a new bioph...

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, wh... [Read more...]

Industry
Biotechnology
IPO Date
Apr 29, 2004
CEO
Robert Blum
Employees
156
Stock Exchange
NASDAQ
Ticker Symbol
CYTK
Full Company Profile

Financial Performance

In 2019, Cytokinetics's revenue was $26.87 million, a decrease of -14.71% compared to the previous year's $31.50 million. Losses were -$121.69 million, 14.5% more than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Cytokinetics stock is "Buy." The 12-month stock price forecast is 27.00, which is an increase of 34.40% from the latest price.

Price Target
$27.00
(34.40% upside)
Analyst Consensus: Buy